Example of one of such vectors developed is Modified Vaccinia virus Ankara (MVA), with mutations in genome and is considered as a safer alternative for humans (10,11).
Marker rescue of the host range restriction defects of modified vaccinia virus Ankara.
Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region.
Modified vaccinia virus Ankara (MVA) is a promising viral vector platform for the development of influenza vaccines (5).
Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases.
The PEACHI Consortium members have employed replication-defective simian adenovirus (ChAd) and modified vaccinia virus Ankara
(MVA) vector technology to develop the most immunogenic HCV and HIV-1 vaccines to date.
Called Imvamune, the vaccine is derived from the parent strain Modified Vaccinia virus Ankara
(MVA-BN), a highly attenuated pox virus that has lost the capacity to replicate in human cells, according to its maker, Bavarian Nordic A/S, a Denmark-based biotechnology company.
A less virulent stock consisting of modified vaccinia virus Ankara
(MVA) stock has shown improved safety in clinical trials.
29) have shown that intranasal or intramuscular inoculations of mice with highly attenuated modified vaccinia virus Ankara
(MVA) vaccines encoding full-length SARS-CoV S protein also produce neutralizing antibodies with mean neutralizing titers of 1:284.
Subsequently, this initial response is then "boosted" using a Modified Vaccinia virus Ankara
(MVA) based vector, which codes for the same hepatitis B specific antigens as the DNA prime.